Patient shareholders are probably more than a little cheesed off, having endured a 70% slide in the stock price since March. Prompted by two profit warnings linked to revenue recognition, a £9.8m placing (169p), the resignation of CEO Pat Clawson and the reshuffling of C-suite responsibilities. Nevertheless, there are reasons for optimism. Why?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rebuilding trust and stability
- Published:
14 Nov 2017 -
Author:
Paul Hill -
Pages:
12
Patient shareholders are probably more than a little cheesed off, having endured a 70% slide in the stock price since March. Prompted by two profit warnings linked to revenue recognition, a £9.8m placing (169p), the resignation of CEO Pat Clawson and the reshuffling of C-suite responsibilities. Nevertheless, there are reasons for optimism. Why?